Navigation Links
Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
Date:6/10/2009

d commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... RUTHERFORD, N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... ended June 30, 2014. Highlights ... $61.6 million in the same period last year. , ... $11.4 million in the same period last year (see table ... 2014 sales guidance increased, excluding the impact of foreign currency, ...
(Date:7/31/2014)... 2014 “2014 Deep Research ... Industry” is a professional and in-depth research ... introduces Polyurethane Resin basic information, including its ... and industry overview. This research covers the ... as well as global industry analysis covering ...
(Date:7/31/2014)... mathematician (1912-1954), is famous for a number of breakthroughs, ... 1936 he published a paper, which laid the foundation ... a computer algorithm. He next played a pivotal role ... cracked the German military codes, enabling the Allies to ... the late 1940,s he turned his attention to artificial ...
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... ... Walker formed MEDS World, LLC, launching innovative odor elimination, exterior plastic trim and headlight ... over fifty years of management experiences, in a myriad of industries, to introduce these ... http://www.meds-world.com , ...
... Fred Hutchinson Cancer Research Center board of trustees today announced ... retire in June 2010. Hartwell, a recipient of the 2001 ... director of the Hutchinson Center since 1997. , ... director of the Center for 12 years. It,s time for ...
... Ga., June 26 Immucor, Inc., (Nasdaq/NM: BLUD), a global ... industry, announced that yesterday the Food and Drug Administration ("FDA"), ... inspection, issued a notice of intent to revoke the Company,s ... and Anti-E (Monoclonal) Blood Grouping Reagent product. The FDA ...
Cached Biology Technology:MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 3Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 2Immucor Responds To FDA Notice 2
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... the photovoltaic effect in 1839, humankind has sought to ... its own purposes. In a new research report published ... FASEB Journal , scientists may have uncovered a ... focusing on a naturally occurring combination of lipids that ... over time and across speciessuggests that this specific natural ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2
... of vitamin C were associated with higher levels of high ... issues or death for heart failure patients, in research presented ... to those with high vitamin C intake from food, heart ... intake were 2.4 times more likely to have higher levels ...
... Clinical benefit from use of a novel histone deacetylase ... days after a patient receives treatment. The drug, entinostat, ... a randomized, placebo-controlled study in metastatic breast cancer ... can be predicted shortly after administration. The findings, ...
... Lysmata amboinensis usually live in monogamous pairs, but ... BioMed Central,s open access journal Frontiers in Zoology ... viciously attack and kill each other until only a single ... hermaphrodites. This means that they start out as males but, ...
Cached Biology News:Low vitamin C levels may raise heart failure patients' risk 2Benefit of novel drug in breast cancer seen in blood within weeks 2Violent passions -- jealous cleaner shrimp murder their rivals 2
in vitro Translation, Accessory Products...
... SAGE (serial analysis of ... genome-wide expression analysis. Expression profiles ... enough to detect low-abundance transcripts ... novel genes. The I-SAGE Kit ...
Sheep Serum US Origin...
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
Biology Products: